^
    3years
    [VIRTUAL] Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting. (ASCO 2021)
    Target enrollment is 50 pts with ALK-fp tumors evaluable by RECIST . As of 9 Feb 2021, 1 pt is in screening.
    P2 data
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK fusion • ALK mutation • ALK F1245C • ALK R1275Q
    |
    Alecensa (alectinib)